Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 4, 2020

View Archived Issues

Cutting off AML's metabolic escape route

Challenges for mutation correction in human embryos

FDA approves Bronchitol inhalation powder for patients with cystic fibrosis

Innovation Pharmaceuticals receives pre-IND response for brilacidin trial in COVID-19

FDA clears IND application for phase I/II study of EG-70 in NMIBC

Adakveo approved in Europe to prevent VOCs in patients with sickle cell disease

Concert initiates phase III THRIVE-AA1 study of CTP-543 for alopecia areata

AT-752 improves survival in mouse model of dengue infection

Nurix Therapeutics patents CBLB inhibitors

Plexxikon discloses KAT3B and CREBBP inhibitors

Bristol Myers Squibb identifies new Gal-3 inhibitors

Nuvation Bio describes new Wee1 inhibitors

Tenaya Therapeutics presents AAV5 compositions

Serine deprivation spurs selective translation in pancreatic cancer

JCR begins global phase I/II trial of JR-171 for MPS I

Combination of donepezil and quetiapine or PDE10A inhibitors provides synergic anti-BuChE activity

Phase III results for molidustat in patients with renal anemia undergoing dialysis

LV20.19, a bispecific CAR T-cell therapy for RR B-cell malignancies: results from phase I trial

Biodistribution, dosimetry and preclinical efficacy data presented for [177Lu]rhPSMA-7.3

New PROTACs synthesized by C4 Therapeutics

BiomX begins first-in-human study of BX-002 phage therapy for IBD

Phase II/III study of voclosporin ophthalmic solution in dry eye does not meet primary endpoint

IO Biotech announces new phase II trial of cancer immunotherapies in head & neck cancer

Aligos begins first-in-human trial of ALG-000184 for chronic hepatitis B

HT-005 reduces skin plaque severity in cutaneous lupus erythematosus mouse model

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...